EnteroBiotix, a leading clinical stage microbiome therapeutics company, has been granted a manufacturers ‘specials’ license from the Medicines and Healthcare Products Regulatory Agency (MHRA) to further its therapeutic and product pipeline.
EnteroBiotix has also appointed senior biotechnology executive Dr James Clark PhD as CEO, with founder Dr James McIIroy moving to the role of Chief Business Officer in order to support the new CEO and accommodate NHS hospital requirements to complete his medical training as a clinician.
James Clark brings over 20 years of biotechnology and biopharmaceutical drug discovery, development and commercialisation experience to EnteroBiotix. Previous roles have included Chief Technical Officer at Enterome, one of Europe’s leading microbiome companies, and most recently Vice-President of clinical laboratory operations at Inivata, the global clinical cancer genomics group.
Dr James McIlroy, EnteroBiotix founder and Chief Business Officer said:
“We are absolutely thrilled to welcome James Clark to the team at this critical inflection point for the business. With the MHRA approval under our belt and a strengthened senior management team, we are well positioned to make an outsized impact in this exciting field of science and medicine. I am grateful to our Board and shareholders for allowing me to continue my NHS medical training alongside my continuing role at EnteroBiotix.”
Dr James Clark PhD, EnteroBiotix CEO, said:
“EnteroBiotix is one the most exciting early stage biopharmaceutical startups in the UK, and is attracting significant investor interest. It’s a great time to lead the company and I look forward to working with James and the rest of the team as we enter the next phase of growth.”
EnteroBiotix is developing novel medicinal products targeting the gut microbiome to serve patients with serious unmet clinical needs. The company has established fully integrated ISO-accredited microbial collection and GMP-compliant processing capabilities under a ‘specials’ license from the MHRA. Headquartered in Aberdeen, EnteroBiotix has to date raised over £2m in equity investment and non-dilutive funding with a dedicated core team supported by an independent Scientific and Medical Advisory Board.